Icariside II from Epimedium koreanum inhibits hypoxia-inducible factor-1alpha in human osteosarcoma cells - PubMed (original) (raw)

. 2008 Jan 28;579(1-3):58-65.

doi: 10.1016/j.ejphar.2007.10.010. Epub 2007 Oct 15.

Affiliations

• PMID: 17980359
• DOI: 10.1016/j.ejphar.2007.10.010

Icariside II from Epimedium koreanum inhibits hypoxia-inducible factor-1alpha in human osteosarcoma cells

Hwa Jung Choi et al. Eur J Pharmacol. 2008.

Abstract

Hypoxia-inducible factor-1 (HIF-1) is an important tumor-selective therapeutic target for solid tumors. Icariside II was isolated from Epimedium koreanum through successive fractionation with ethyl acetate, n-butanol, chloroform and hexane, followed by gel column chromatography. Icariside II attenuated the protein level of HIF-1alpha induced by hypoxia in human osteosarcoma (HOS) cells in a concentration-dependent manner, probably by enhancing the interaction rate between von Hippel-Lindau (VHL) and HIF-1alpha. Furthermore, Icariside II down-regulated the levels of HIF-inducible genes involved in angiogenesis, metastasis, and glucose metabolism, such as vascular endothelial growth factor (VEGF), urokinase plasminogen activator receptor (uPAR), adrenomedullin (ADM), matrix metalloproteinase 2 (MMP2), aldolase A, and enolase 1 in HOS cells. Icariside II also inhibited the migration rate in HOS cells and tube formation rate in human umbilical vein endothelium cells (HUVECs). Overall, these results suggest the potential use of Icariside II as a therapeutic candidate against various diseases that involve overexpression of HIF-1alpha.

PubMed Disclaimer

Similar articles

• An activator of PHD2, KRH102140, decreases angiogenesis via inhibition of HIF-1α.
  Nepal M, Gong YD, Park YR, Soh Y. Nepal M, et al. Cell Biochem Funct. 2011 Mar;29(2):126-34. doi: 10.1002/cbf.1732. Epub 2011 Feb 1. Cell Biochem Funct. 2011. PMID: 21287578
• Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids.
  Fernando W, Rupasinghe HP, Hoskin DW. Fernando W, et al. Mini Rev Med Chem. 2015;15(6):479-89. doi: 10.2174/1389557515666150414152933. Mini Rev Med Chem. 2015. PMID: 25873069 Review.
• Therapeutic effects of icariin and icariside II on diabetes mellitus and its complications.
  Jiang W, Ding K, Yue R, Lei M. Jiang W, et al. Crit Rev Food Sci Nutr. 2024;64(17):5852-5877. doi: 10.1080/10408398.2022.2159317. Epub 2023 Jan 2. Crit Rev Food Sci Nutr. 2024. PMID: 36591787 Review.

Cited by

• Icariside II: Anticancer Potential and Molecular Targets in Solid Cancers.
  Xu F, Wu Q, Li L, Gong J, Huo R, Cui W. Xu F, et al. Front Pharmacol. 2021 Apr 26;12:663776. doi: 10.3389/fphar.2021.663776. eCollection 2021. Front Pharmacol. 2021. PMID: 33981241 Free PMC article. Review.
• Baohuoside-I suppresses cell proliferation and migration by up-regulating miR-144 in melanoma.
  Peng YG, Zhang L. Peng YG, et al. Pharm Biol. 2018 Dec;56(1):43-50. doi: 10.1080/13880209.2017.1418391. Pharm Biol. 2018. PMID: 29260980 Free PMC article.
• Advancements in the Biotransformation and Biosynthesis of the Primary Active Flavonoids Derived from Epimedium.
  Zhang X, Tang B, Wen S, Wang Y, Pan C, Qu L, Yin Y, Wei Y. Zhang X, et al. Molecules. 2023 Oct 19;28(20):7173. doi: 10.3390/molecules28207173. Molecules. 2023. PMID: 37894651 Free PMC article. Review.
• Anti-Cancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and Its Derivatives.
  Tan HL, Chan KG, Pusparajah P, Saokaew S, Duangjai A, Lee LH, Goh BH. Tan HL, et al. Front Pharmacol. 2016 Jun 29;7:191. doi: 10.3389/fphar.2016.00191. eCollection 2016. Front Pharmacol. 2016. PMID: 27445824 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Miscellaneous

  • NCI CPTAC Assay Portal